Herriot Tabuteau Sells 78,703 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CEO Herriot Tabuteau sold 78,703 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $171.28, for a total value of $13,480,249.84. Following the transaction, the chief executive officer directly owned 7,229 shares in the company, valued at $1,238,183.12. The trade was a 91.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Herriot Tabuteau also recently made the following trade(s):

• On Tuesday, January 6th, Herriot Tabuteau sold 29,450 shares of Axsome Therapeutics stock. The shares were sold at an average price of $172.33, for a total value of $5,075,118.50.
• On Wednesday, January 7th, Herriot Tabuteau sold 31,261 shares of Axsome Therapeutics stock. The stock was sold at an average price of $170.38, for a total value of $5,326,249.18.
• On Thursday, December 4th, Herriot Tabuteau sold 10,558 shares of Axsome Therapeutics stock. The shares were sold at an average price of $148.18, for a total transaction of $1,564,484.44.
• On Tuesday, December 2nd, Herriot Tabuteau sold 49,252 shares of Axsome Therapeutics stock. The stock was sold at an average price of $144.59, for a total value of $7,121,346.68.
• On Wednesday, December 3rd, Herriot Tabuteau sold 20,163 shares of Axsome Therapeutics stock. The shares were sold at an average price of $146.94, for a total value of $2,962,751.22.
• On Tuesday, November 4th, Herriot Tabuteau sold 50,459 shares of Axsome Therapeutics stock. The stock was sold at an average price of $133.79, for a total value of $6,750,909.61.
• On Wednesday, November 5th, Herriot Tabuteau sold 21,775 shares of Axsome Therapeutics stock. The shares were sold at an average price of $134.49, for a total value of $2,928,519.75.
• On Monday, November 3rd, Herriot Tabuteau sold 91,705 shares of Axsome Therapeutics stock. The stock was sold at an average price of $132.34, for a total value of $12,136,239.70.

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM traded down $1.19 during trading on Wednesday, reaching $170.69. The company had a trading volume of 814,950 shares, compared to its average volume of 1,023,813. Axsome Therapeutics, Inc. has a 12 month low of $79.19 and a 12 month high of $184.40. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66. The company has a fifty day moving average of $148.79 and a two-hundred day moving average of $126.76. The stock has a market capitalization of $8.60 billion, a P/E ratio of -36.55, a price-to-earnings-growth ratio of 11.99 and a beta of 0.44.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). The firm had revenue of $170.99 million during the quarter, compared to analysts’ expectations of $162.96 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The business’s revenue for the quarter was up 63.2% compared to the same quarter last year. Equities research analysts forecast that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on AXSM. Royal Bank Of Canada lifted their price objective on shares of Axsome Therapeutics from $189.00 to $198.00 and gave the company an “outperform” rating in a report on Tuesday, November 4th. Morgan Stanley restated an “overweight” rating on shares of Axsome Therapeutics in a research report on Wednesday, December 31st. Cowen restated a “buy” rating on shares of Axsome Therapeutics in a research note on Wednesday, December 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Wednesday, October 8th. Finally, Mizuho set a $217.00 target price on Axsome Therapeutics in a research note on Wednesday, December 31st. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $191.88.

Institutional Trading of Axsome Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Allworth Financial LP grew its stake in Axsome Therapeutics by 6.6% in the 3rd quarter. Allworth Financial LP now owns 1,442 shares of the company’s stock worth $175,000 after acquiring an additional 89 shares during the period. Moors & Cabot Inc. boosted its position in Axsome Therapeutics by 4.5% during the 2nd quarter. Moors & Cabot Inc. now owns 2,330 shares of the company’s stock worth $243,000 after purchasing an additional 100 shares during the period. Meridian Wealth Management LLC grew its stake in shares of Axsome Therapeutics by 0.5% in the third quarter. Meridian Wealth Management LLC now owns 22,124 shares of the company’s stock valued at $2,687,000 after buying an additional 103 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Axsome Therapeutics by 65.4% during the fourth quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock valued at $49,000 after purchasing an additional 106 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in Axsome Therapeutics by 1.1% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 9,889 shares of the company’s stock valued at $1,032,000 after buying an additional 107 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.